Regulus Therapeutics Inc. (RGLS)
NASDAQ: RGLS · Real-Time Price · USD
1.590
+0.040 (2.58%)
Dec 20, 2024, 4:00 PM EST - Market closed
Regulus Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Revenue | - | - | - | - | 10.01 | 6.83 | Upgrade
|
| Revenue Growth (YoY) | - | - | - | - | 46.46% | 9388.89% | Upgrade
|
| Cost of Revenue | 22.62 | 21.15 | 18.41 | 17.79 | 15.35 | 12.35 | Upgrade
|
| Gross Profit | -22.62 | -21.15 | -18.41 | -17.79 | -5.34 | -5.52 | Upgrade
|
| Selling, General & Admin | 13.14 | 9.96 | 9.83 | 10.02 | 8.81 | 11.32 | Upgrade
|
| Operating Expenses | 21.97 | 9.96 | 9.83 | 10.02 | 8.81 | 11.32 | Upgrade
|
| Operating Income | -44.59 | -31.11 | -28.24 | -27.82 | -14.16 | -16.83 | Upgrade
|
| Interest Expense | -0.26 | -0.6 | -0.69 | -0.86 | -1.81 | -2.13 | Upgrade
|
| Interest & Investment Income | 3.23 | 1.68 | 0.61 | 0.2 | 0.23 | 0.37 | Upgrade
|
| EBT Excluding Unusual Items | -41.63 | -30.04 | -28.32 | -28.47 | -15.73 | -18.59 | Upgrade
|
| Other Unusual Items | - | - | - | 0.66 | - | - | Upgrade
|
| Pretax Income | -41.63 | -30.04 | -28.32 | -27.81 | -15.73 | -18.59 | Upgrade
|
| Income Tax Expense | 0 | 0 | 0 | 0 | - | 0 | Upgrade
|
| Net Income | -41.63 | -30.04 | -28.32 | -27.81 | -15.73 | -18.59 | Upgrade
|
| Net Income to Common | -41.63 | -30.04 | -28.32 | -27.81 | -15.73 | -18.59 | Upgrade
|
| Shares Outstanding (Basic) | 45 | 19 | 15 | 9 | 3 | 2 | Upgrade
|
| Shares Outstanding (Diluted) | 45 | 19 | 15 | 9 | 3 | 2 | Upgrade
|
| Shares Change (YoY) | 148.48% | 24.25% | 78.07% | 145.01% | 102.65% | 97.97% | Upgrade
|
| EPS (Basic) | -0.92 | -1.58 | -1.86 | -3.24 | -4.50 | -10.77 | Upgrade
|
| EPS (Diluted) | -0.92 | -1.58 | -1.86 | -3.24 | -4.50 | -10.77 | Upgrade
|
| Free Cash Flow | -36.36 | -27.38 | -25.89 | -24.38 | -12.54 | -20.04 | Upgrade
|
| Free Cash Flow Per Share | -0.81 | -1.44 | -1.70 | -2.84 | -3.58 | -11.61 | Upgrade
|
| Gross Margin | - | - | - | - | -53.38% | -80.75% | Upgrade
|
| Operating Margin | - | - | - | - | -141.47% | -246.40% | Upgrade
|
| Profit Margin | - | - | - | - | -157.21% | -272.13% | Upgrade
|
| Free Cash Flow Margin | - | - | - | - | -125.28% | -293.35% | Upgrade
|
| EBITDA | -44.26 | -30.88 | -28.12 | -27.36 | -13.69 | -15.9 | Upgrade
|
| EBITDA Margin | - | - | - | - | -136.80% | -232.77% | Upgrade
|
| D&A For EBITDA | 0.34 | 0.23 | 0.12 | 0.46 | 0.47 | 0.93 | Upgrade
|
| EBIT | -44.59 | -31.11 | -28.24 | -27.82 | -14.16 | -16.83 | Upgrade
|
| EBIT Margin | - | - | - | - | -141.47% | -246.40% | Upgrade
|
| Revenue as Reported | - | - | - | - | 10.01 | 6.83 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.